Cresco Labs Q1 2026 Earnings: $151M Revenue Meets the Schedule III Tax Reset

Cresco Labs reported first-quarter 2026 results on May 8, 2026, posting $151 million in revenue and $33 million in adjusted EBITDA against a $17 million net loss. The headline numbers were respectable for a U.S. multi-state operator (MSO) navigating mature-market pricing pressure, but the story shareholders are watching unfolded after the quarter closed — when the Department of Justice's April 23 order moved FDA-approved cannabis products and qualifying state-licensed medical cannabis into Schedule III, eliminating Section 280E for Cresco's medical operations.

The combination of stable operations, expansion in Ohio, and a long-awaited tax reset is reshaping the financial profile of Cresco and the broader MSO peer group. Here is what the quarter actually showed.

The Quarter in Numbers

Cresco's Q1 2026 revenue of $151 million reflected the now-familiar combination of resilient unit volume and softer per-unit pricing across legacy mature markets. Gross profit came in at $75 million, producing a gross margin near 50 percent — a level Cresco has worked to defend as wholesale flower and concentrate pricing has compressed.

Adjusted EBITDA of $33 million translated to a margin of 21.7 percent, comfortably in the range MSO investors expect from a top-five operator. The $17 million net loss, while still red ink, reflects non-cash charges and the persistent drag of 280E taxes accrued during the quarter — taxes that will substantially diminish for the company's medical business going forward.

The release emphasized cost discipline and operational leverage, with the company highlighting that adjusted EBITDA grew slightly even on revenue that softened year over year. That trajectory matters for refinancing conversations and for the broader MSO narrative that 2026 represents an inflection point rather than another step down.

What Schedule III Actually Changes

The April 23, 2026 DOJ order placing FDA-approved cannabis products and qualifying state-licensed medical cannabis into Schedule III is the most consequential federal cannabis policy change in more than half a century. For an MSO like Cresco, the most immediate impact is the end of Section 280E for medical operations.

Section 280E is a provision of the Internal Revenue Code that prohibits any business "trafficking in" a Schedule I or Schedule II controlled substance from deducting ordinary business expenses. For cannabis operators, that has historically meant effective federal tax rates of 70 percent or more — a structural drag that has consumed cash flow even at profitable operators.

By moving qualifying medical cannabis out of Schedule I, the DOJ order lifts the 280E ceiling on Cresco's medical sales. The company has indicated it expects "substantial cash tax savings" as the policy takes effect through ongoing implementation. For an MSO with significant medical exposure, the cumulative annual benefit could run into the tens of millions.

It is important to be precise about what Schedule III did not do. It did not legalize adult-use cannabis at the federal level. It did not change state cannabis laws. And it did not eliminate 280E for adult-use operations, which remain in a more complicated regulatory posture. The relief applies to the medical channel and to FDA-approved cannabis products. The adult-use side of MSO businesses still operates in the previous tax environment until and unless federal policy moves further.

Cresco's DEA Registration Filing

Alongside earnings, Cresco confirmed it has filed applications for DEA registration to operate under Schedule III for the qualifying medical business. That registration is the procedural step that allows the company to formally take advantage of the reschedule.

Several large MSO peers, including Curaleaf and Glass House Brands, have filed similar applications. The DEA's pace in processing these registrations will materially affect when operators can begin reflecting the tax savings in reported earnings. Industry counsel has flagged this implementation window — late 2026 into 2027 — as a key variable.

The registration process also surfaces the new compliance architecture that comes with Schedule III. Medical cannabis under the new framework remains tightly regulated and is subject to a different set of recordkeeping, distribution, and prescribing requirements than purely state-legal cannabis. MSOs will need to maintain parallel compliance systems for medical (federal Schedule III) and adult-use (state-only) products.

Expansion: Ohio Comes Online

Cresco's Q1 update included two new Ohio dispensaries — Bridgeport on April 10, 2026 and Aberdeen on May 5, 2026 — bringing fresh adult-use revenue into the second-quarter pipeline. Ohio's adult-use market, which launched after the November 2023 ballot win, has matured rapidly and remains one of the most attractive new state markets in the country.

The company also confirmed it is providing management services to nine Pennsylvania dispensaries — a positioning move ahead of any potential adult-use legalization in the Commonwealth. Pennsylvania remains a medical-only market as of May 2026, but management services agreements allow operators to build retail relationships and operational presence without committing capital to assets that depend on policy change.

That Pennsylvania exposure is strategically meaningful. With Governor Shapiro making his third consecutive push for adult-use legalization and SB 120 still alive in the state Senate, MSOs with PA infrastructure stand to benefit disproportionately from any breakthrough.

How the Market Read the Print

Cannabis stocks have spent much of 2025 and 2026 trading on policy headlines rather than operational results, and Q1 earnings season has reinforced that pattern. CRLBF and peers moved more on the rescheduling implementation timeline than on revenue beats or misses, and analyst commentary has shifted toward 2027 cash-flow models that assume meaningful 280E relief.

Tier-one MSOs are also positioning for a possible SAFER Banking package, additional state-level adult-use openings (Pennsylvania, Florida re-litigation, Hawaii medical-to-adult), and continued progress on uplisting to U.S. major exchanges should federal policy continue to evolve. None of those catalysts are certainties, but the Schedule III reset has materially improved the base case.

The Profit Path From Here

For Cresco specifically, the path back to GAAP profitability runs through three lines on the income statement. First, 280E relief lifts the effective tax rate as Schedule III implementation takes hold across medical sales. Second, operating leverage from new Ohio dispensaries and the Pennsylvania management book should absorb fixed costs and lift adjusted EBITDA. Third, continued cost discipline — particularly on G&A and interest expense — has to compound across multiple quarters.

The Q1 print suggests management is executing on the second and third items. The first depends on regulatory mechanics that are largely outside the company's control but are now moving in a more favorable direction than at any prior point in U.S. cannabis history.

Key Takeaways

• Cresco Labs posted Q1 2026 revenue of $151 million, gross profit of $75 million, adjusted EBITDA of $33 million (21.7 percent margin), and a net loss of $17 million.
• The April 23, 2026 DOJ Schedule III order eliminated Section 280E for FDA-approved cannabis and qualifying state-licensed medical cannabis, materially lifting Cresco's medical tax burden.
• Cresco has filed DEA registration applications required to operate under Schedule III for its medical business.
• Two new Ohio dispensaries (Bridgeport and Aberdeen) opened in April and May 2026, with management services covering nine Pennsylvania dispensaries.
• Adult-use cannabis remains outside the Schedule III relief; MSO cash flows will improve most where medical exposure is highest.

Explore cannabis news, find dispensaries, and join the community at Budpedia.